Spark, Pfizer amend agreement for experimental hemophilia gene therapy – Philadelphia Business Journal
Philadelphia Business Journal |
Spark, Pfizer amend agreement for experimental hemophilia gene therapy
Philadelphia Business Journal Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children’s Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical trial testing the treatment known as … Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia BStreetInsider.com |
Technology Networks |
Autonomously Growing Synthetic DNA Strands
Technology Networks Synthetic biologists and nanobiologists are re-purposing DNA, the hereditary material present in nearly all the body’s cells, as a smart and stable self-assembling material to build nanofactories, drug-delivering nanostructures and molecular devices … |
Technology Networks |
Autonomously Growing Synthetic DNA Strands
Technology Networks Synthetic biologists and nanobiologists are re-purposing DNA, the hereditary material present in nearly all the body’s cells, as a smart and stable self-assembling material to build nanofactories, drug-delivering nanostructures and molecular devices … |
EurekAlert (press release) |
A ‘CRISPR‘ view of Sturge-Weber syndrome is coming into focus
EurekAlert (press release) Three-dimensional modeling and CRISPR-Cas9 gene editing technology are giving scientists a new view into Sturge-Weber syndrome, a rare congenital disorder that causes small blood vessels, called capillaries, to be malformed. These capillary … |
Endpoints News |
FDA Lifts Clinical Hold on Cellectis CAR–T Trials
Genetic Engineering & Biotechnology News (blog) Cellectis said the FDA has lifted the clinical hold placed in September on the company’s two Phase I studies of its universal gene-edited allogeneic chimeric antigen receptor T–cell (CAR-T) immunotherapy candidate UCART123 following the death of a … FDA lifts clinical hold on Cellectis CAR–TBioPharma Dive FDA gives Cellectis a green light to relaunch off-the-shelf CAR–T studies — with several strings attachedEndpoints News FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCNBusiness Wire (press release) |